Cardiol Therapeutics Net Worth
Cardiol Therapeutics Net Worth Breakdown | CRDL |
Cardiol Therapeutics Net Worth Analysis
Cardiol Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cardiol Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cardiol Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cardiol Therapeutics' net worth analysis. One common approach is to calculate Cardiol Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cardiol Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cardiol Therapeutics' net worth. This approach calculates the present value of Cardiol Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cardiol Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cardiol Therapeutics' net worth. This involves comparing Cardiol Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cardiol Therapeutics' net worth relative to its peers.
To determine if Cardiol Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cardiol Therapeutics' net worth research are outlined below:
| Cardiol Therapeutics generated a negative expected return over the last 90 days | |
| Cardiol Therapeutics may become a speculative penny stock | |
| Cardiol Therapeutics has high historical volatility and very poor performance | |
| Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (28.13 K) with profit before overhead, payroll, taxes, and interest of 78.76 K. | |
| Cardiol Therapeutics Class currently holds about 70.45 M in cash with (25.18 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14. |
Cardiol Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cardiol Therapeutics Class. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cardiol Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Cardiol Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 116.16 M. Cardiol Therapeutics time-series forecasting models is one of many Cardiol Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardiol Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Cardiol Therapeutics Earnings per Share Projection vs Actual
Cardiol Therapeutics Corporate Management
| Andrew MD | Chief Development | Profile | |
| Trevor Burns | Investor Relations | Profile | |
| Bernard BSc | Chief Officer | Profile | |
| MBA BSCPT | Vice Development | Profile | |
| MBA MBA | CEO Pres | Profile | |
| CA CMA | Corp CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.